Antiplatelet therapy in acute coronary syndromes

Bibliography

• Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357(24):2482-94
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Wojta J, et al. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012;18(33):5197-214
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541-619
   PubMed Web of Science ®Google Scholar
• Kristensen SD, Wurtz M, Grove EL, et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost 2012;107(2):215-24
   PubMed Web of Science ®Google Scholar
• Grove EL, Kristensen SD. Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiol 2009;5(3):247-58
   PubMedGoogle Scholar
• Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18(33):5344-61
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353(22):2373-83
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376(9754):1741-50
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol 1988;12(6 Suppl A):3A-13A
   PubMed Web of Science ®Google Scholar
• Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316(7141):1337-43
   PubMed Web of Science ®Google Scholar
• Lewis HDJr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(7):396-403
   PubMed Web of Science ®Google Scholar
• Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313(22):1369-75
   PubMed Web of Science ®Google Scholar
• Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319(17):1105-11
   PubMed Web of Science ®Google Scholar
• Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990;336(8719):827-30
   PubMed Web of Science ®Google Scholar
• Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376(9748):1233-43
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363(10):930-42
   PubMed Web of Science ®Google Scholar
• Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108(14):1682-7
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63(4):421-30
   PubMed Web of Science ®Google Scholar
• Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(Suppl 2):15-19
   PubMed Web of Science ®Google Scholar
• Funck-Jensen KL, Dalsgaard J, Grove EL, et al. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets 2013;24(7):528-37
   PubMed Web of Science ®Google Scholar
• Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122(6):776-81
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301(9):937-44
   PubMed Web of Science ®Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57(11):1251-63
   PubMed Web of Science ®Google Scholar
• Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34(23):1708-13b
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153(1):66.e9-16
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25(4):357-74
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116(25):2923-32
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118(16):1626-36
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367(14):1297-309
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27(4):259-74
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56(18):1456-62
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120(25):2577-85
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Varenhorst C, Alstrom U, Braun OO, et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart 2014;100(22):1762-9
   PubMed Web of Science ®Google Scholar
• Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014;25(7):517-25
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012;17(2):164-72
   PubMed Web of Science ®Google Scholar
• Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014;19(2):209-19
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014;63(9):872-7
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014;63(23):2503-9
   PubMed Web of Science ®Google Scholar
• Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36(19):1163-70
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372(19):1791-800
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054
   PubMed Web of Science ®Google Scholar
• Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes. N Engl J Med 2013;369(11):999-1010
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, Kerneis M, O’Connor SA, et al. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ 2014;349:g6269
   PubMed Web of Science ®Google Scholar
• Montalescot G, van ’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014;371(11):1016-27
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009;7(10):1195-201
   PubMedGoogle Scholar
• Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13(7):407-13
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361(24):2318-29
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361(24):2330-41
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368(14):1303-13
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382(9909):1981-92
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307(3):265-74
   PubMed Web of Science ®Google Scholar
• Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6(7):1153-9
   PubMed Web of Science ®Google Scholar
• Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 2012;5(3):336-46
   PubMed Web of Science ®Google Scholar
• Chintala M, Shimizu K, Ogawa M, et al. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 2008;108(4):433-8
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366(1):20-33
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366(15):1404-13
   PubMed Web of Science ®Google Scholar
• Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013;44(3):691-8
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 2012;380(9850):1317-24
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349(9063):1429-35
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295(13):1531-8
   PubMed Web of Science ®Google Scholar
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339(7):436-43
   PubMed Web of Science ®Google Scholar
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338(21):1488-97
   PubMed Web of Science ®Google Scholar
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338(21):1498-505
   PubMed Web of Science ®Google Scholar
• Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. Jama 2007;297(6):591-602
   PubMed Web of Science ®Google Scholar
• Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360(21):2176-90
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for Patients with Acute Coronary Syndromes. N Engl J Med 2006;355(21):2203-16
   PubMed Web of Science ®Google Scholar
• Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365(21):1980-9
   PubMed Web of Science ®Google Scholar
• Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357(9272):1905-14
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358(9282):605-13
   PubMed Web of Science ®Google Scholar
• De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009;30(22):2705-13
   PubMed Web of Science ®Google Scholar
• Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358(21):2205-17
   PubMed Web of Science ®Google Scholar
• Van’t Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372(9638):537-46
   PubMed Web of Science ®Google Scholar
• Heestermans AA, Van Werkum JW, Hamm C, et al. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. J Thromb Haemost 2009;7(10):1612-18
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377(9784):2193-204
   PubMed Web of Science ®Google Scholar
• Steg PG, van ’t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369(23):2207-17
   PubMed Web of Science ®Google Scholar
• Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118(1):49-57
   PubMed Web of Science ®Google Scholar
• Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 2010;121(6):784-91
   PubMed Web of Science ®Google Scholar
• Thiele H, Wohrle J, Neuhaus P, et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 2010;159(4):547-54
   PubMed Web of Science ®Google Scholar
• Iversen A, Abildgaard U, Galloe A, et al. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial. J Interv Cardiol 2011;24(2):105-11
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307(17):1817-26
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336(7637):195-8
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011;9:185-91
   PubMed Web of Science ®Google Scholar
• Grove EL, Gregersen S. Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol 2012;10(4):494-505
   PubMed Web of Science ®Google Scholar
• Grove EL, Storey RF, Kristensen SD. Can we improve the efficacy of low-dose aspirin? Thromb Haemost 2014;112(6):1077-8
   PubMed Web of Science ®Google Scholar
• Pettersen AA, Seljeflot I, Abdelnoor M, et al. High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc 2012;1(3):e000703
   Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011;162(4):733-9
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121(10):1188-99
   PubMed Web of Science ®Google Scholar
• Wurtz M, Lordkipanidze M, Grove EL. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost 2013;11(9):1627-39
   PubMed Web of Science ®Google Scholar
• Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012;18(33):5379-91
   PubMed Web of Science ®Google Scholar
• Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306(11):1215-23
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305(11):1097-105
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103(1):5-10
   PubMed Web of Science ®Google Scholar
• Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58(5):467-73
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371(23):2155-66
   PubMed Web of Science ®Google Scholar
• Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35(45):3155-79
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381(9872):1107-5
   PubMed Web of Science ®Google Scholar
• Martin JF, Kristensen SD, Mathur A, et al. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012;9(11):658-70
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009;101(1):151-6
   PubMed Web of Science ®Google Scholar